Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Osteoporosis Drugs No Overall Heart Risk

Posted by Jane Akre
Thursday, November 13, 2008 10:51 PM EST
Category: Major Medical, Protecting Your Family
Tags: Dangerous Drugs, Osteoporosis, FDA and Prescription Drugs

Clinical trials on osteoporisis drugs did not link it to AF

LEARN MORE

 

IMAGESOURCE: ©iStockPhoto/ osteoporatic hips/ Starfotograph

 

A red flag was raised last year on a class of drugs known as bisphosphonates, used to treat thinning bones from osteoporosis.

The FDA now says that clinical follow-up trials show no overall risk of heart problems associated with the drugs.

In an article in the May 2007, New England Journal of Medicine (NEJM), two different studies of women ages 65 to 89 with osteoporosis were treated with Reclast and Fosamax.

Data available to the FDA showed an increased risk of serious atrial fibrillation (AF). The Reclast label was changed to reflect the risk. 

As a result of these findings, in October 2007, the FDA began collecting safety data on 40,000 patients. Half had been given a bisphosphonates and half a placebo. The patients were followed for six month to three years.

The occurrence of AF was rare with two or fewer events reported.

“Across all studies, no clear association between overall bisphosphonate exposure and the rate of serious or non-serious atrial fibrillation was observed.  Increasing dose or duration of bisphosphonate therapy was also not associated with an increased rate of atrial fibrillation,” according to the FDA in a release Wednesday.

The FDA now says that healthcare professionals should not alter their prescribing patterns for bisphosphonates.

The popular bisphosphonates are:

  • Fosamax (alendronate) Merck & Co
  • Didronel (etidronate) Procter and Gamble
  • Boniva (ibandronate) Roche Holding AG
  • Aredia (palidronate) Novartis
  • Actonel (risedronate) Procter and Gamble
  • Skelid (tiludronate) Sanofi Aventis
  • Reclast, Zometa (zoledronic acid) Novartis

One large study of zoledronic acid showed a statistically significant increase in AF events, but it was not associated to the drug exposure or the duration of time on the drug. Reclast is the once yearly injectable bisphosphonate.

Still some questions linger about how this class of drugs affects the heart beat. The FDA has not ruled out additional epidemiologic studies on the issue.

Possible severe pain is already a recognized side effect among some taking the drugs.

Bisphosphonates work by slowing the bone turnover which normally occurs. The drug class is also used to treat patients with Paget’s disease of the bone and to treat bone metastases.

AF is not uncommon in individuals over the age of 65, the same age as many in the study last year.  

During AF, the heart’s upper chambers quiver instead of beat. The heart stops pumping blood effectively and the risk raises for blood clots.  15 percent of strokes occur in people with AF.  

Anyone who has had adverse side effects from this class of drugs is asked to report the use of bisphosphonates to the FDA MedWatch Adverse Event Reporting Program. #


1 Comment

Anonymous User
Posted by reddit_monster
Wednesday, November 19, 2008 9:49 PM EST

You can search all adverse events reported to the FDA here:

e.g., this is a search for adverse events for Reclast (as mentioned in the article above): LINK

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes